The echinocandins
- PMID: 17316149
- DOI: 10.1592/phco.27.3.369
The echinocandins
Abstract
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin. These agents have a broad spectrum of activity and are similar to each other with respect to in vitro activity against Candida sp, with micafungin and anidulafungin having similar minimum inhibitory concentrations (MICs) that are generally lower than the MIC of capsofungin. The MICs of the echinocandins are highest against Candida parapsilosis; however, whether this will affect clinical outcomes is unknown. Several case reports have identified clinical failure due to elevated MICs with caspofungin or micafungin against Candida albicans, Candida krusei, and C. parapsilosis. Resistance to the echinocandin class was present in some but not all of the isolates. Empiric therapy with one of the echinocandins for candidemia or invasive candidiasis in patients with neutropenia and those without neutropenia appears to be appropriate when one factors in mortality rate, the increasing frequency of non-albicans Candida infections, and the broad spectrum, safety, and fungicidal effect of the echinocandins. After speciation of the organism, continued therapy with an echinocandin can and should be reevaluated. The echinocandins demonstrate similar in vitro and in vivo activity against Aspergillus sp, but only caspofungin is approved for treatment in patients who are intolerant of or refractory to other therapies. Voriconazole and amphotericin B have demonstrated synergy with the echinocandins. The clinical response to combination therapy has been variable; however, the mortality rate appears to be lower with combination therapy than monotherapy. Large controlled trials are needed to determine the role of combination therapy for invasive aspergillosis. Micafungin and anidulafungin generally have a lower frequency of adverse reactions compared with caspofungin. Phlebitis (3.5-25% of patients) and elevated liver enzyme levels (1-15%) occur more often with caspofungin compared with micafungin and anidulafungin (< 8%). Overall, the three echinocandins are relatively safe and effective agents for the treatment of Candida infections.
Similar articles
-
Echinocandin antifungal drugs in fungal infections: a comparison.Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000. Drugs. 2011. PMID: 21175238 Review.
-
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol. 2003 Dec;20(4):121-36. Rev Iberoam Micol. 2003. PMID: 15456349 Review.
-
Micafungin: a new echinocandin.Clin Infect Dis. 2006 Apr 15;42(8):1171-8. doi: 10.1086/501020. Epub 2006 Mar 14. Clin Infect Dis. 2006. PMID: 16575738 Review.
-
Echinocandins: the newest class of antifungals.Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. Ann Pharmacother. 2009. PMID: 19724014 Review.
-
Echinocandins in the management of invasive fungal infections, Part 2.Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. doi: 10.2146/ajhp050464.p2. Am J Health Syst Pharm. 2006. PMID: 16990627 Review.
Cited by
-
Candida albicans exhibits heterogeneous and adaptive cytoprotective responses to antifungal compounds.Elife. 2023 Oct 27;12:e81406. doi: 10.7554/eLife.81406. Elife. 2023. PMID: 37888959 Free PMC article.
-
The in vitro Activity of Echinocandins Against Clinical Trichophyton rubrum Isolates and Review of the Susceptibility of T. rubrum to Echinocandins Worldwide.Infect Drug Resist. 2023 Aug 18;16:5395-5403. doi: 10.2147/IDR.S423735. eCollection 2023. Infect Drug Resist. 2023. PMID: 37621698 Free PMC article.
-
Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.Mycopathologia. 2023 Oct;188(5):667-681. doi: 10.1007/s11046-023-00727-z. Epub 2023 Apr 26. Mycopathologia. 2023. PMID: 37100963 Free PMC article. Review.
-
Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations.Infect Drug Resist. 2023 Apr 12;16:2167-2178. doi: 10.2147/IDR.S372546. eCollection 2023. Infect Drug Resist. 2023. PMID: 37077251 Free PMC article. Review.
-
Post-transcriptional control of antifungal resistance in human fungal pathogens.Crit Rev Microbiol. 2023 Aug;49(4):469-484. doi: 10.1080/1040841X.2022.2080527. Epub 2022 May 28. Crit Rev Microbiol. 2023. PMID: 35634915 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical